Cork-based Solvotrin Therapeutics is poised to take on the $15 billion anti-platelet market with the development of its worldwide protected bio-activated Aspirin drug that delivers all the benefits without the side effect of gastro-intestinal bleeding.
Commenting on the new venture, serial entrepreneur and co-founder, Mr. Pat O’Flynn said, “This is an innovative breakthrough which will further contribute to making Cork and indeed Ireland a centre of excellence for the pharma industry. I am very excited about the company’s market potential. Our research has shown that the market demands a solution to the side effects of Aspirin and our drug directly addresses this problem allowing us to gain immediate market share in the vast and growing anti-platelet market”.
Pat O’Flynn was introduced by Enterprise Ireland through the Business Partner Programme and Technology Transfer Offices at TCD to co-founder Dr John Gilmer, who has spent over 10 years working with the Aspirin drug.
Aspirin is one of the most prescribed drugs in the world and is used to prevent clotting, heart attacks, stroke and death in patients with cardiovascular disease. However, up to 75% of patients using Aspirin have detectable levels of gastric bleeding. Dr. Gilmer discovered that he could deactivate Aspirin to protect the stomach and intestine lining, allowing it be activated later by enzymes naturally present in the blood, thereby liberating active aspirin only when it is in the bloodstream. In this way, the drug maintains its therapeutic qualities, without the damaging gastrointestinal side effects.
“Commercialising 4th level research is vital for the future of Ireland’s economy. Highly innovative and ground breaking research has been ongoing in our universities and colleges in recent years. Now, more than ever, Ireland Inc. needs to ensure that this research is brought to market, creating viable jobs and increasing Ireland’s profile internationally”, stated Mr. O’Flynn. “As a Board member of Cork Chamber, I am committed to promoting our region as the location of choice for foreign multinationals seeking research partners to address global markets”.
The Solvotrin Management Team consists of Pat O’Flynn, Dr John Gilmer, Dr Mark Ledwidge and John O’Flynn. Pat O’Flynn is an entrepreneur with over fifteen years experience in the pharmaceutical industry and was recently recognised by the Ernst & Young Entrepreneur of the Year programme. Dr John Gilmer, who heads up Solvotrin’s research team, is an expert scientist in drug discovery and development and a lecturer at the School of Pharmacy and Pharmaceutical Sciences. Dr Mark Ledwidge is an entrepreneur and a researcher in cardiovascular disease in St. Vincent’s University Hospital, Dublin and the School of Medicine, University College Dublin. John O’Flynn is a principal in the OFactum Group and is an experienced business person with international business interests. Solvotrin has also attracted some of the most prestigious Professors in the area to advice on the development process.